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Early diagnosis and treatment: the goal of hepatitis C
screening
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Koretz and colleagues correctly highlight the need for robust
evidence for hepatitis C screening, but a few points warrant a
more balanced discussion.1
The impact of hepatitis C should not be underestimated. Deaths
associated with hepatitis C trebled in the UK between 1996 and
2010. By 2020, an estimated 15 480 infected people in the UK
will have associated cirrhosis or hepatocellular carcinoma.2
The US birth cohort screening programme the authors described
has shown cost effectiveness.3 Newer regimens will ultimately
improve pricing competition and sustained virological response
(SVR) rates compared with interferon based treatments. The
authors question the benefit of achieving SVR, despite a
meta-analysis of 34 563 treated patients showing a 62%
reduction in all cause mortality.4
The article focuses on whether risks of treatment outweigh
benefits. Previous reports suggest achieving SVR is associated
with improved quality of life.5 Traditional interferon based
treatments have serious side effects. However, newer direct
acting antiviral regimens have greater tolerability. One study
that the authors cited used a sofosbuvir and ledipasvir regimen.1
Of 647 treated patients only three (0.5%) discontinued treatment
early because of side effects. Ten (1.5%) experienced serious
adverse events. However, it is unclear howmany of these events
were genuinely attributable to these drugs.
Patients successfully treated with mild to moderate disease may
be alarmed to read the authors’ interpretation of SVR. These
patients should be reassured that ongoing hepatitis C mediated
liver damage is unlikely. Reactivation after SVR is exceedingly
rare. Conversely, patients with cirrhosis are at risk of disease
progression after SVR. This emphasises the importance of early
diagnosis and treatment, which is the ultimate goal of screening.
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